Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Paloma Pharmaceuticals, Inc.
Age
50–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Best corrected visual acuity in the study eye between 20/100 and 20/800 (between 53 and 4 ETDRS letters read), and better or equal to 20/200 (minimum of 34 letters read) in the fellow eye.
Subfoveal choroidal neovascularization (CNV) due to AMD
Total area of the lesion (including blood, neovascularization and scar/atrophy) must be \< 12 DA.
Only 1 eye will be treated in the study. If both eyes are eligible, the investigator will select the eye with the most active CNV
Clear ocular media and adequate pupillary dilatation to permit good stereo fundus photography for screening
Intraocular pressure of 21 mm Hg or less
Retinal thickness ≥ 250 μm by OCT, with presence of intraretinal or subretinal fluid
You may not be if
Any retinovascular disease or retinal degeneration other than AMD
Serous pigment epithelial detachment without the presence of neovascularization
Previous posterior vitrectomy or retinal surgery
Any periocular infection in the past 4 weeks
Concomitant therapy with anti-VEGF therapies, e.g. Avastin, Lucentis or Macugen, or previous use of these agents within 60 days of screening
Concomitant therapy with intravenous or intravitreous corticosteroids or use within 90 days of screening
Significant media opacities, including cataract, which might interfere with visual acuity, assessment of toxicity, or fundus photography
Cataract surgery in the study eye within 3 months of screening
Intraocular surgery in the study eye within 3 months of screening
Presence of ocular infection in the study eye
Presence of severe myopia (-8 diopters or greater) in the study eye
